Details of Disease

General Information of Disease (ID: DIS3LXUG)

Disease Name Cutaneous squamous cell carcinoma
Synonyms
CSCC; zone of skin squamous cell carcinoma; squamous cell skin carcinoma; squamous cell carcinoma of the skin; squamous cell carcinoma of skin; squamous cell carcinoma - skin; skin squamous cell carcinoma; skin squamous cell cancer; epidermoid skin carcinoma; epidermoid carcinoma of the skin; epidermoid carcinoma of skin; cutaneous squamous cell carcinoma
Disease Class 2C30: Melanoma
Definition A carcinoma arising from the squamous cells of the epidermis. Skin squamous cell carcinoma is most commonly found on sun-exposed areas. The majority of the tumors are well-differentiated.
Disease Hierarchy
DISUZREN: Skin carcinoma
DISQVIFL: Squamous cell carcinoma
DIS3LXUG: Cutaneous squamous cell carcinoma
ICD Code
ICD-11
ICD-11: 2C30
Expand ICD-11
'2C31.Z
Disease Identifiers
MONDO ID
MONDO_0002529
UMLS CUI
C0553723
MedGen ID
107512
HPO ID
HP:0006739
SNOMED CT ID
254651007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 3 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Cemiplimab DMKMJHE Approved Monoclonal antibody [1]
Paclitaxel DMLB81S Approved Small molecular drug [2]
Pembrolizumab DMFQEA6 Approved Monoclonal antibody [3]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
CLL442 DMFUXSP Phase 1/2 NA [4]
Ifx-Hu2.0 DM637SC Phase 1 Vaccine [5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 28 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ATF3 TTCE793 Limited Altered Expression [6]
EPHA1 TTLFZVU Limited Altered Expression [7]
KLKB1 TTN0PCX Limited Biomarker [8]
KRT17 TTKV0EC Limited Biomarker [9]
KYNU TTWQM3J Limited Altered Expression [10]
MAP3K4 TT1RSX7 Limited Altered Expression [11]
MAP3K9 TTUNSIX Limited Altered Expression [11]
MAPKAP1 TTWDKCL Limited Biomarker [12]
RIPK4 TTB4S01 Limited Biomarker [8]
SERPINB3 TT6QLPX Limited Altered Expression [13]
SLCO1B3 TTU86P0 Limited Altered Expression [14]
USP8 TT1J07C Limited Altered Expression [15]
WWP1 TTBWMKT Limited Altered Expression [16]
CD200 TT0BE68 moderate Biomarker [17]
CD274 TT8ZLTI moderate Altered Expression [18]
LGR5 TTTSGRH moderate Biomarker [19]
RSPO1 TTI9HL4 moderate Genetic Variation [20]
SLC6A2 TTAWNKZ moderate Biomarker [21]
SLC6A5 TTI0138 moderate Biomarker [21]
AHR TT037IE Strong Altered Expression [22]
COL7A1 TTBCOKN Strong Genetic Variation [14]
CYP21A2 TTP4GLG Strong Genetic Variation [23]
FGF10 TTNPEFX Strong Altered Expression [24]
IRF3 TTYR7OH Strong Genetic Variation [23]
MC1R TT0MV2T Strong Genetic Variation [25]
PCSK6 TT75LN9 Strong Altered Expression [26]
RAC1 TT2M9CG Strong Genetic Variation [23]
TYR TTULVH8 Definitive Genetic Variation [25]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC45A2 DTNCJAT Definitive Genetic Variation [25]
------------------------------------------------------------------------------------
This Disease Is Related to 1 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
SCLY DEH4TD6 Strong Biomarker [27]
------------------------------------------------------------------------------------
This Disease Is Related to 95 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ANKRD36B OT3MW415 Limited Biomarker [28]
CARD11 OTRCTLYC Limited Genetic Variation [29]
CARD14 OTADQHOV Limited Altered Expression [29]
CAVIN1 OTFO915U Limited Altered Expression [30]
CCL8 OTCTWYN8 Limited Biomarker [31]
CCRL2 OT5PX0RX Limited Biomarker [32]
CD200R1 OT65Q9M6 Limited Altered Expression [33]
CDK16 OTUBXIIT Limited Biomarker [34]
CFDP1 OTXY7J96 Limited Altered Expression [15]
CKS1B OTNUPLUJ Limited Biomarker [35]
CLDN11 OTNN6UTL Limited Biomarker [36]
CLEC2D OTVRLKPM Limited Altered Expression [37]
CRIP2 OTVVJSYX Limited Biomarker [38]
CSHL1 OTQKU2F5 Limited Biomarker [39]
CTNNA1 OTFC725Z Limited Altered Expression [40]
CTTN OTJRG4ES Limited Biomarker [41]
DEF8 OTS93PPZ Limited Genetic Variation [42]
DLX3 OTARP5SQ Limited Altered Expression [43]
DPH3 OT59Q6C4 Limited Genetic Variation [44]
EFS OT06O7XL Limited Genetic Variation [12]
EGR3 OTGPJIRA Limited Altered Expression [45]
EIF4G2 OTEO98CR Limited Altered Expression [15]
ERBIN OTNWTUA8 Limited Genetic Variation [42]
FAM114A2 OTINDFMX Limited Altered Expression [46]
FOXG1 OTAW57J4 Limited Biomarker [47]
G0S2 OT8FL49L Limited Altered Expression [48]
GEMIN4 OTX7402E Limited Altered Expression [15]
HERC2 OTNQYKOB Limited Genetic Variation [49]
HOXA9 OTKNK5H0 Limited Biomarker [50]
IVL OT4VPNGY Limited Biomarker [51]
KPNA4 OTP0EX18 Limited Biomarker [52]
KRT16 OTGA0EQN Limited Biomarker [45]
KRT72 OTAXW63A Limited Biomarker [9]
KTN1 OTQAV541 Limited Biomarker [53]
LAMC1 OTIG527N Limited Altered Expression [54]
LZTS1 OTXXL864 Limited Altered Expression [55]
MAGEA12 OT8ULELL Limited Biomarker [28]
MAL OTBM30SW Limited Biomarker [56]
MMUT OTBBBV70 Limited Biomarker [57]
MRGBP OTXBPDMS Limited Altered Expression [58]
NBPF1 OTAZ55UQ Limited Altered Expression [59]
NSD2 OTQ6SW4R Limited Biomarker [60]
PARD3 OTH5BPLO Limited Biomarker [61]
PCBP1 OTHN0TD7 Limited Biomarker [62]
POLQ OTBHK0E6 Limited Genetic Variation [63]
POLR3E OT69PWBM Limited Genetic Variation [12]
PRAF2 OT1QN4LV Limited Altered Expression [64]
PSMD2 OT6HZHN7 Limited Altered Expression [15]
PTPRD OTZPJ3GX Limited Genetic Variation [65]
RAB23 OTBAKFBR Limited Biomarker [66]
RAB25 OTW0W6NP Limited Altered Expression [67]
RETREG1 OTYOSLZX Limited Biomarker [68]
RHOBTB1 OTGE8K45 Limited Biomarker [69]
RNF2 OTFPLOIN Limited Biomarker [70]
SEM1 OTASLBM1 Limited Genetic Variation [71]
SERPINB9 OTJ811IF Limited Altered Expression [72]
SIN3A OTM8OZWV Limited Biomarker [73]
SMPX OTLSHGBF Limited Biomarker [39]
SPRR1A OTJMI34A Limited Altered Expression [74]
SRCIN1 OTQZNQQ5 Limited Biomarker [75]
ST3GAL1 OTFCO8QX Limited Genetic Variation [42]
STAT2 OTO9G2RZ Limited Altered Expression [76]
STT3A OTDPS6AV Limited Biomarker [77]
TAF15 OTNE038N Limited Altered Expression [78]
TCF7L1 OTTUTF0O Limited Altered Expression [79]
TP53RK OTARRZAB Limited Biomarker [80]
TRIM16 OTLRXYOZ Limited Biomarker [81]
TRIM32 OTJOV0PG Limited Altered Expression [82]
COL17A1 OTID5AH2 moderate Altered Expression [83]
FOXE1 OT5IR5IT moderate Biomarker [84]
FUT1 OTODG57A moderate Biomarker [85]
NET1 OTZHNMJV moderate Biomarker [21]
POLH OTN07WXU moderate Genetic Variation [86]
PRPF38B OTQLH551 moderate Biomarker [21]
BCL2L12 OTS6IFZY Strong Genetic Variation [23]
CRNKL1 OTWBQNGU Strong Genetic Variation [23]
CYFIP1 OTOBEH24 Strong Altered Expression [87]
GRHL3 OT1V4ZEH Strong Altered Expression [88]
INPP5A OT9CMGMS Strong Altered Expression [89]
KNSTRN OTYA7UXS Strong Genetic Variation [90]
KRT7 OTLT3JFN Strong Biomarker [27]
OCA2 OTDWIGBF Strong Genetic Variation [49]
OVOL1 OTFJ62UI Strong Altered Expression [91]
OVOL2 OTFM1GKF Strong Altered Expression [91]
RARRES2 OT1BJE8K Strong Biomarker [92]
SERPINB4 OT88LHZ8 Strong Altered Expression [93]
STK19 OTYM6437 Strong Genetic Variation [23]
TAL1 OTX4K6QZ Strong Biomarker [27]
TMC8 OTUAD95X Strong Genetic Variation [94]
TSPAN1 OTZQPIYK Strong Biomarker [21]
IRF4 OT1DHQ1P Definitive Genetic Variation [25]
LPP OT6TU8SE Definitive Genetic Variation [25]
RALY OT78NNWY Definitive Genetic Variation [25]
SEC16A OTFNQ1ZU Definitive Genetic Variation [25]
TRPS1 OT7XPPEL Definitive Genetic Variation [25]
------------------------------------------------------------------------------------
⏷ Show the Full List of 95 DOT(s)

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 Paclitaxel FDA Label
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT04160065) Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC. U.S. National Institutes of Health.
6 The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes.J Dermatol Sci. 2018 Nov;92(2):172-180. doi: 10.1016/j.jdermsci.2018.08.013. Epub 2018 Sep 5.
7 Silencing of EPHB2 promotes the epithelial-mesenchymal transition of skin squamous cell carcinoma-derived A431 cells.Oncol Lett. 2019 Apr;17(4):3735-3742. doi: 10.3892/ol.2019.10019. Epub 2019 Feb 6.
8 PKK suppresses tumor growth and is decreased in squamous cell carcinoma of the skin.J Invest Dermatol. 2015 Mar;135(3):869-876. doi: 10.1038/jid.2014.428. Epub 2014 Oct 6.
9 Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients.BMC Cancer. 2013 Feb 5;13:58. doi: 10.1186/1471-2407-13-58.
10 Downregulation of kynureninase restrains cutaneous squamous cell carcinoma proliferation and represses the PI3K/AKT pathway.Clin Exp Dermatol. 2020 Mar;45(2):194-201. doi: 10.1111/ced.14072. Epub 2019 Sep 26.
11 Role of miR-148a in cutaneous squamous cell carcinoma by repression of MAPK pathway.Arch Biochem Biophys. 2015 Oct 1;583:47-54. doi: 10.1016/j.abb.2015.07.022. Epub 2015 Aug 5.
12 Expression and function of NET-1 in human skin squamous cell carcinoma.Arch Dermatol Res. 2014 May;306(4):385-97. doi: 10.1007/s00403-013-1423-9. Epub 2013 Nov 7.
13 Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma.JCI Insight. 2018 Sep 6;3(17):e120750. doi: 10.1172/jci.insight.120750. eCollection 2018 Sep 6.
14 Type VII collagen regulates expression of OATP1B3, promotes front-to-rear polarity and increases structural organisation in 3D spheroid cultures of RDEB tumour keratinocytes.J Cell Sci. 2014 Feb 15;127(Pt 4):740-51. doi: 10.1242/jcs.128454. Epub 2013 Dec 19.
15 The Identification of Potential TherapeuticTargets for Cutaneous SquamousCell Carcinoma.J Invest Dermatol. 2020 Jun;140(6):1154-1165.e5. doi: 10.1016/j.jid.2019.09.024. Epub 2019 Nov 6.
16 WW domain-containing E3 ubiquitin protein ligase 1 depletion evokes antitumor effect in cutaneous squamous cell carcinoma by inhibiting signal transducer and activator of transcription 3 signaling pathway.J Int Med Res. 2018 Jul;46(7):2898-2912. doi: 10.1177/0300060518778905. Epub 2018 Jun 10.
17 Over-Expression of CD200 Predicts Poor Prognosis in Cutaneous Squamous Cell Carcinoma.Med Sci Monit. 2016 Apr 1;22:1079-84. doi: 10.12659/msm.895245.
18 Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma.Asia Pac J Clin Oncol. 2020 Apr;16(2):e108-e112. doi: 10.1111/ajco.13102. Epub 2018 Nov 8.
19 Inactivation of TGF receptors in stem cells drives cutaneous squamous cell carcinoma.Nat Commun. 2016 Aug 25;7:12493. doi: 10.1038/ncomms12493.
20 R-spondin1 is essential in sex determination, skin differentiation and malignancy. Nat Genet. 2006 Nov;38(11):1304-9. doi: 10.1038/ng1907. Epub 2006 Oct 15.
21 Inhibition of skin squamous cell carcinoma proliferation and promote apoptosis by dual silencing of NET-1 and survivin.Oncol Rep. 2015 Aug;34(2):811-22. doi: 10.3892/or.2015.4062. Epub 2015 Jun 15.
22 Activation and overexpression of the aryl hydrocarbon receptor contribute to cutaneous squamous cell carcinomas: an immunohistochemical study.Diagn Pathol. 2018 Aug 25;13(1):59. doi: 10.1186/s13000-018-0740-x.
23 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
24 Pten loss induces autocrine FGF signaling to promote skin tumorigenesis.Cell Rep. 2014 Mar 13;6(5):818-26. doi: 10.1016/j.celrep.2014.01.045. Epub 2014 Feb 27.
25 Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma.Nat Commun. 2016 Jul 18;7:12048. doi: 10.1038/ncomms12048.
26 Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis.Neoplasia. 2010 Jul;12(7):516-26. doi: 10.1593/neo.92030.
27 Fibulin-3 Has Anti-Tumorigenic Activities inCutaneous Squamous Cell Carcinoma.J Invest Dermatol. 2019 Aug;139(8):1798-1808.e5. doi: 10.1016/j.jid.2019.01.022. Epub 2019 Feb 6.
28 Overexpression and Implications of Melanoma-associated Antigen A12 in Pathogenesis of Human Cutaneous Squamous Cell Carcinoma.Anticancer Res. 2019 Apr;39(4):1849-1857. doi: 10.21873/anticanres.13292.
29 Novel CARD11 Mutations in Human Cutaneous Squamous Cell Carcinoma Lead to Aberrant NF-B Regulation.Am J Pathol. 2015 Sep;185(9):2354-63. doi: 10.1016/j.ajpath.2015.05.018. Epub 2015 Jul 26.
30 MiR-217 promotes cutaneous squamous cell carcinoma progression by targeting PTRF.Am J Transl Res. 2017 Feb 15;9(2):647-655. eCollection 2017.
31 CCL8 enhances sensitivity of cutaneous squamous cell carcinoma to photodynamic therapy by recruiting M1 macrophages.Photodiagnosis Photodyn Ther. 2019 Jun;26:235-243. doi: 10.1016/j.pdpdt.2019.03.014. Epub 2019 Mar 19.
32 Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration.Oncotarget. 2016 Dec 13;7(50):83554-83569. doi: 10.18632/oncotarget.13446.
33 CD200 upregulation in vascular endothelium surrounding cutaneous squamous cell carcinoma.JAMA Dermatol. 2013 Feb;149(2):178-86. doi: 10.1001/jamadermatol.2013.1609.
34 PCTAIRE1/CDK16/PCTK1 is overexpressed in cutaneous squamous cell carcinoma and regulates p27 stability and cell cycle.J Dermatol Sci. 2017 May;86(2):149-157. doi: 10.1016/j.jdermsci.2017.02.281. Epub 2017 Feb 22.
35 CKS1B amplification is a frequent event in cutaneous squamous cell carcinoma with aggressive clinical behaviour.Genes Chromosomes Cancer. 2010 Nov;49(11):1054-61. doi: 10.1002/gcc.20814.
36 Expression of claudin-11 by tumor cells in cutaneous squamous cell carcinoma is dependent on the activity of p38.Exp Dermatol. 2017 Sep;26(9):771-777. doi: 10.1111/exd.13278. Epub 2017 Apr 10.
37 Lectin-like transcript 1 (LLT1) expression is associated with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.Arch Dermatol Res. 2019 Jul;311(5):369-376. doi: 10.1007/s00403-019-01916-x. Epub 2019 Apr 6.
38 HOXA9 inhibits HIF-1-mediated glycolysis through interacting with CRIP2 to repress cutaneous squamous cell carcinoma development.Nat Commun. 2018 Apr 16;9(1):1480. doi: 10.1038/s41467-018-03914-5.
39 CSL controls telomere maintenance and genome stability in human dermal fibroblasts.Nat Commun. 2019 Aug 29;10(1):3884. doi: 10.1038/s41467-019-11785-7.
40 E-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway.Genes Dev. 2016 Apr 1;30(7):798-811. doi: 10.1101/gad.274951.115. Epub 2016 Mar 24.
41 The Pathogenic Effect of Cortactin Tyrosine Phosphorylation in Cutaneous Squamous Cell Carcinoma.In Vivo. 2019 Mar-Apr;33(2):393-400. doi: 10.21873/invivo.11486.
42 A Genome-Wide Association Study of Cutaneous Squamous Cell Carcinoma among European Descendants.Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):714-20. doi: 10.1158/1055-9965.EPI-15-1070. Epub 2016 Feb 12.
43 A novel DLX3-PKC integrated signaling network drives keratinocyte differentiation.Cell Death Differ. 2017 Apr;24(4):717-730. doi: 10.1038/cdd.2017.5. Epub 2017 Feb 10.
44 Frequent DPH3 promoter mutations in skin cancers.Oncotarget. 2015 Nov 3;6(34):35922-30. doi: 10.18632/oncotarget.5771.
45 Identification of Biomarker for Cutaneous Squamous Cell Carcinoma Using Microarray Data Analysis.J Cancer. 2018 Jan 1;9(2):400-406. doi: 10.7150/jca.21381. eCollection 2018.
46 miR-497 promotes the progression of cutaneous squamous cell carcinoma through FAM114A2.Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7348-7355. doi: 10.26355/eurrev_201811_16272.
47 miR-30a-5p modulates traits of cutaneous squamous cell carcinoma (cSCC) via forkhead box protein G1 (FOXG1).Neoplasma. 2019 Nov;66(6):908-917. doi: 10.4149/neo_2018_181205N923. Epub 2019 Jun 28.
48 Silencing of G0/G1 switch gene 2 in cutaneous squamous cell carcinoma.PLoS One. 2017 Oct 26;12(10):e0187047. doi: 10.1371/journal.pone.0187047. eCollection 2017.
49 Variants at the OCA2/HERC2 locus affect time to first cutaneous squamous cell carcinoma in solid organ transplant recipients collected using two different study designs.Br J Dermatol. 2017 Oct;177(4):1066-1073. doi: 10.1111/bjd.15618. Epub 2017 Sep 8.
50 HOXA9 Transcriptionally Promotes Apoptosis and Represses Autophagy by Targeting NF-B in Cutaneous Squamous Cell Carcinoma.Cells. 2019 Oct 31;8(11):1360. doi: 10.3390/cells8111360.
51 Altered gene expression in squamous cell carcinoma arising from congenital unilateral linear porokeratosis.Clin Exp Dermatol. 2012 Oct;37(7):781-5. doi: 10.1111/j.1365-2230.2012.04393.x.
52 MiR-3619-5p hampers proliferation and cisplatin resistance in cutaneous squamous-cell carcinoma via KPNA4.Biochem Biophys Res Commun. 2019 May 28;513(2):419-425. doi: 10.1016/j.bbrc.2019.03.203. Epub 2019 Apr 6.
53 MALAT1-KTN1-EGFR regulatory axis promotes the development of cutaneous squamous cell carcinoma.Cell Death Differ. 2019 Oct;26(10):2061-2073. doi: 10.1038/s41418-019-0288-7. Epub 2019 Jan 25.
54 miR-506 contributes to malignancy of cutaneous squamous cell carcinoma via targeting of P65 and LAMC1.Cell Cycle. 2019 Feb;18(3):333-345. doi: 10.1080/15384101.2019.1568747. Epub 2019 Jan 24.
55 MicroRNA-135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous Squamous Cell Carcinoma.PLoS One. 2015 May 4;10(5):e0125412. doi: 10.1371/journal.pone.0125412. eCollection 2015.
56 Effect of Methyl Aminolevulinate Photodynamic Therapy With and Without Ablative Fractional Laser Treatment in Patients With Microinvasive Squamous Cell Carcinoma: A Randomized Clinical Trial.JAMA Dermatol. 2017 Mar 1;153(3):289-295. doi: 10.1001/jamadermatol.2016.4463.
57 Expression of Minichromosome Maintenance Proteins in Actinic Keratosis and Squamous Cell Carcinoma.Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):165-172. doi: 10.1097/PAI.0000000000000399.
58 Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma.Oncogene. 2011 Nov 17;30(46):4666-77. doi: 10.1038/onc.2011.180. Epub 2011 May 23.
59 Effects of neuroblastoma breakpoint family member 1 (NBPF1) gene on growth and Akt-p53-Cyclin D pathway in cutaneous squamous carcinoma cells.Neoplasma. 2019 Jul 23;66(4):584-592. doi: 10.4149/neo_2018_181123N888. Epub 2019 Apr 24.
60 Inhibitory effect of microRNA-154 targeting WHSC1 on cell proliferation of human skin squamous cell carcinoma through mediating the P53 signaling pathway.Int J Biochem Cell Biol. 2018 Jul;100:22-29. doi: 10.1016/j.biocel.2018.04.021. Epub 2018 May 1.
61 Mutational landscape of aggressive cutaneous squamous cell carcinoma.Clin Cancer Res. 2014 Dec 15;20(24):6582-92. doi: 10.1158/1078-0432.CCR-14-1768. Epub 2014 Oct 10.
62 Poly r(C) binding protein is post-transcriptionally repressed by MiR-490-3p to potentiate squamous cell carcinoma.Tumour Biol. 2016 Nov;37(11):14773-14778. doi: 10.1007/s13277-016-5234-4. Epub 2016 Sep 15.
63 Mutations in DNA polymerase eta are not detected in squamous cell carcinoma of the skin.Int J Cancer. 2006 Nov 1;119(9):2225-7. doi: 10.1002/ijc.22099.
64 Long non-coding RNA HOTAIR functions as a competitive endogenous RNA to regulate PRAF2 expression by sponging miR-326 in cutaneous squamous cell carcinoma.Cancer Cell Int. 2019 Oct 21;19:270. doi: 10.1186/s12935-019-0992-x. eCollection 2019.
65 Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.Int J Cancer. 2012 Aug 1;131(3):E216-26. doi: 10.1002/ijc.27333. Epub 2011 Dec 21.
66 Rab23 promotes squamous cell carcinoma cell migration and invasion via integrin 1/Rac1 pathway.Oncotarget. 2016 Feb 2;7(5):5342-52. doi: 10.18632/oncotarget.6701.
67 Loss of Rab25 promotes the development of skin squamous cell carcinoma through the dysregulation of integrin trafficking.J Pathol. 2019 Oct;249(2):227-240. doi: 10.1002/path.5311. Epub 2019 Jul 18.
68 MicroRNA-186 promotes cell proliferation and inhibits cell apoptosis in cutaneous squamous cell carcinoma by targeting RETREG1.Exp Ther Med. 2019 Mar;17(3):1930-1938. doi: 10.3892/etm.2019.7154. Epub 2019 Jan 7.
69 MicroRNA-31 functions as an oncogenic microRNA in cutaneous squamous cell carcinoma cells by targeting RhoTBT1.Oncol Lett. 2017 Mar;13(3):1078-1082. doi: 10.3892/ol.2017.5554. Epub 2017 Jan 2.
70 The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.Carcinogenesis. 2018 Mar 8;39(3):503-513. doi: 10.1093/carcin/bgy016.
71 Association of the DSS1 c.143G>A polymorphism with skin squamous cell carcinoma.J Invest Dermatol. 2010 Jun;130(6):1719-25. doi: 10.1038/jid.2010.21. Epub 2010 Mar 11.
72 Disrupted regulation of serpinB9 in circulating T cells is associated with an increased risk for post-transplant skin cancer.Clin Exp Immunol. 2019 Sep;197(3):341-351. doi: 10.1111/cei.13309. Epub 2019 May 30.
73 Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth.Cancer Res. 2017 Oct 1;77(19):5301-5312. doi: 10.1158/0008-5472.CAN-17-0418. Epub 2017 Aug 14.
74 Clinical significance of SPRR1A expression in progesterone receptor-positive breast cancer.Tumour Biol. 2015 Apr;36(4):2601-5. doi: 10.1007/s13277-014-2879-8. Epub 2014 Nov 26.
75 MicroRNA-346 functions as an oncogene in cutaneous squamous cell carcinoma.Tumour Biol. 2016 Feb;37(2):2765-71. doi: 10.1007/s13277-015-4046-2. Epub 2015 Sep 26.
76 Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cells.Mol Cancer Ther. 2003 May;2(5):453-9.
77 Risk of Cutaneous Squamous Cell Carcinoma Development in Renal Transplant Recipients Is Independent of TMC/EVER Alterations.Dermatology. 2015;231(3):245-52. doi: 10.1159/000435910. Epub 2015 Jul 28.
78 USF1-induced upregulation of LINC01048 promotes cell proliferation and apoptosis in cutaneous squamous cell carcinoma by binding to TAF15 to transcriptionally activate YAP1.Cell Death Dis. 2019 Apr 1;10(4):296. doi: 10.1038/s41419-019-1516-2.
79 TCF7L1 promotes skin tumorigenesis independently of -catenin through induction of LCN2.Elife. 2017 May 3;6:e23242. doi: 10.7554/eLife.23242.
80 Targeting PRPK and TOPK for skin cancer prevention and therapy.Oncogene. 2018 Oct;37(42):5633-5647. doi: 10.1038/s41388-018-0350-9. Epub 2018 Jun 14.
81 TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells.Oncotarget. 2014 Oct 30;5(20):10127-39. doi: 10.18632/oncotarget.2466.
82 Novel initiation genes in squamous cell carcinomagenesis: a role for substrate-specific ubiquitylation in the control of cell survival.Mol Carcinog. 2007 Aug;46(8):585-90. doi: 10.1002/mc.20344.
83 Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy.Appl Immunohistochem Mol Morphol. 2008 Oct;16(5):433-41. doi: 10.1097/PAI.0b013e318162f8aa.
84 FOXE1 is a target for aberrant methylation in cutaneous squamous cell carcinoma.Br J Dermatol. 2010 May;162(5):1093-7. doi: 10.1111/j.1365-2133.2009.09560.x. Epub 2009 Oct 21.
85 Tamoxifen inhibits the proliferation of nonmelanoma skin cancer cells by increasing intracellular calcium concentration.Int J Oncol. 2018 Nov;53(5):2157-2166. doi: 10.3892/ijo.2018.4548. Epub 2018 Aug 31.
86 The human POLH gene is not mutated, and is expressed in a cohort of patients with basal or squamous cell carcinoma of the skin.Int J Mol Med. 2007 Apr;19(4):589-96.
87 CYFIP1 is directly controlled by NOTCH1 and down-regulated in cutaneous squamous cell carcinoma.PLoS One. 2017 Apr 14;12(4):e0173000. doi: 10.1371/journal.pone.0173000. eCollection 2017.
88 Threonine 454 phosphorylation in Grainyhead-like 3 is important for its function and regulation by the p38 MAPK pathway.Biochim Biophys Acta Mol Cell Res. 2018 Jul;1865(7):1002-1011. doi: 10.1016/j.bbamcr.2018.04.010. Epub 2018 Apr 25.
89 Prognostic value of inositol polyphosphate-5-phosphatase expression in recurrent and metastatic cutaneous squamous cell carcinoma.J Am Acad Dermatol. 2020 Apr;82(4):846-853. doi: 10.1016/j.jaad.2019.08.027. Epub 2019 Aug 19.
90 Somatic mutations in kinetochore gene KNSTRN are associated with basal proliferating actinic keratoses and cutaneous squamous cell carcinoma.J Eur Acad Dermatol Venereol. 2019 Aug;33(8):1535-1540. doi: 10.1111/jdv.15615. Epub 2019 May 8.
91 Potential role of the OVOL1-OVOL2 axis and c-Myc in the progression of cutaneous squamous cell carcinoma.Mod Pathol. 2017 Jul;30(7):919-927. doi: 10.1038/modpathol.2016.169. Epub 2017 Mar 24.
92 Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin Carcinogenesis.Front Oncol. 2019 Nov 15;9:1253. doi: 10.3389/fonc.2019.01253. eCollection 2019.
93 SCCA2-like serpins mediate genetic predisposition to skin tumors.Cancer Res. 2003 Apr 15;63(8):1871-5.
94 A coding variant in TMC8 (EVER2) is associated with high risk HPV infection and head and neck cancer risk.PLoS One. 2015 Apr 8;10(4):e0123716. doi: 10.1371/journal.pone.0123716. eCollection 2015.